Company intelligence / Profile preview
TSH Biopharm Corporation Limited
Taipei, Taiwaneng.tshbiopharm.com ↗
- Ownership
- Private
- Employees
- ~76
- Development stage
- Other
01
Overview
The company has successfully completed bridging studies meeting primary endpoints for RNTA06 in chronic angina. It has multiple NDAs submitted and approved products like TuNEX. It also holds commercialization rights to liquid biopsy diagnostic products via partnership with CellMax Life in Taiwan[1][3].
- Therapeutic areas
- GastroenterologyImmunologyCardiovascular
- Modalities
- Small molecules (cardiovascular drugs, gastroenterology drugs, CNS drugs)Precision medical testing products including liquid biopsy diagnostics
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
InnoPharmax reauthorizationCellMax Cayman investmentCellMax Life
Beyond the preview
Go deeper on TSH Biopharm Corporation Limited.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TSH Biopharm Corporation Limited.